These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35834907)

  • 1. Periorbital edema associated with alpelisib.
    Dao EA; George SJ; Heberton MM; Pacha O; Kovitz CA; Patel AB; Phillips RM
    Cancer Treat Res Commun; 2022; 32():100596. PubMed ID: 35834907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
    Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
    Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpelisib: First Global Approval.
    Markham A
    Drugs; 2019 Jul; 79(11):1249-1253. PubMed ID: 31256368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
    André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
    Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
    Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
    Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.
    Schutte T; Zeverijn LJ; Geurts BS; de Wit GF; Kok M; Opdam FL
    Oncologist; 2023 Jul; 28(7):e493-e497. PubMed ID: 37086483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
    Narayan P; Prowell TM; Gao JJ; Fernandes LL; Li E; Jiang X; Qiu J; Fan J; Song P; Yu J; Zhang X; King-Kallimanis BL; Chen W; Ricks TK; Gong Y; Wang X; Windsor K; Rhieu SY; Geiser G; Banerjee A; Chen X; Reyes Turcu F; Chatterjee DK; Pathak A; Seidman J; Ghosh S; Philip R; Goldberg KB; Kluetz PG; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1842-1849. PubMed ID: 33168657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpelisib for the treatment of
    Leenhardt F; Alexandre M; Jacot W
    Expert Opin Pharmacother; 2021 Apr; 22(6):667-675. PubMed ID: 33622114
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
    Jain S; Shah AN; Santa-Maria CA; Siziopikou K; Rademaker A; Helenowski I; Cristofanilli M; Gradishar WJ
    Breast Cancer Res Treat; 2018 Sep; 171(2):371-381. PubMed ID: 29850984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
    JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
    Blow T; Hyde PN; Falcone JN; Neinstein A; Vasan N; Chitkara R; Hurd MA; Sardesai S; Lustberg MB; Flory JH; Volek JS; Goncalves MD
    Integr Cancer Ther; 2021; 20():15347354211032283. PubMed ID: 34259084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
    Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
    Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
    Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
    Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
    Bello Roufai D; Gonçalves A; De La Motte Rouge T; Akla S; Blonz C; Grenier J; Gligorov J; Saghatchian M; Bailleux C; Simon H; Desmoulins I; Tharin Z; Renaud E; Bertho M; Benderra MA; Delaloge S; Robert L; Cottu P; Pierga JY; Loirat D; Bertucci A; Renouf B; Bidard FC; Lerebours F
    Oncogene; 2023 Jun; 42(23):1951-1956. PubMed ID: 36611120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
    Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
    Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics and Pharmacodynamic of Alpelisib.
    Royer B; Kaderbhaï CG; Schmitt A
    Clin Pharmacokinet; 2023 Jan; 62(1):45-53. PubMed ID: 36633813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpelisib to treat breast cancer.
    Copur MS
    Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.
    Lu YS; Lee KS; Chao TY; Tseng LM; Chitapanarux I; Chen SC; Liu CT; Sohn J; Kim JH; Chang YC; Yang Y; Shotelersuk K; Jung KH; Valenti R; Slader C; Gao M; Park YH
    Clin Cancer Res; 2021 Jan; 27(2):408-417. PubMed ID: 32718997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.